In a phase II study (NCT01754376), high response rates (overall response rate was 83.3% at 6 weeks) were observed in patients with unresectable stage III or IV melanoma harboring BRAFV600E mutation treated with vemurafenib and HD IL-2 (153). Here, IL2 is linked to melanoma.